When to choose VV ECMO? When to choose VA ECMO? Contraindications Initial setup & targets VV ECMO (oxygenation/CO₂) VA ECMO (perfusion/oxygenation) Anticoagulation (Heparin) Default Hold/lighten if ECMO Troubleshooting Problem Likely Causes Key Actions Low SpO₂ (VV ECMO) • Recirculation (cannula malposition)• Inadequate blood flow• Hypovolemia• Oxygenator dysfunction • Check cannula position and flows• Increase blood…
Evaluation of BCG-Denmark vaccine’s effect on Covid-19 risk among healthcare workers Study design International, double-blind, placebo-controlled trial Population Interventions Primary outcome: Symptomatic Covid-19 and severe Covid-19 by 6 months Secondary outcomes Hazard ratio for any Covid-19 episode: 1.23 (95% CI, 0.96 to 1.59) Safety outcomes Adverse Events BCG Group Placebo Group Serious 20 9 Potential…
Study design RCT Population Interventions Primary outcome: % Metastasis at 15 years Secondary outcomes Outcome Active-monitoring Prostatectomy Radiotherapy Metastases 51 26 27 Long-term ADT initiation 69 40 42 Clinical progression 141 58 60 Potential Issues and Biases Since the trial’s inception, treatments and diagnostic methods have evolved. Investigators were not using contemporary multiparametric MRI or…
Cigarette Smoking & Health ImpactCigarette smoking remains the leading preventable cause of illness and death in the United States, with one in eight adults smoking. Most smokers are aware of health risks but struggle to quit due to nicotine dependence. In 2018, 55% of smokers attempted to quit, but only 7.5% succeeded. FDA Regulation &…
Basal Insulin Fc (BIF) vs Degludec in Type 1 Diabetes Patients Using Multiple Daily Injections Study design: Phase 2, randomized, parallel, open-label study Population: 265 patients with type 1 diabetes (T1D) using multiple daily injections Interventions Primary outcome: HbA1c change from baseline to week 26 Secondary/ Safety outcomes Safety Outcomes BIF once weekly HbA1c change…
Does the combination of fluvoxamine and inhaled budesonide increase treatment effects in a highly vaccinated population with early COVID-19? Study design Randomized, placebo-controlled, adaptive platform trial. Population Interventions Primary outcome: Composite of emergency setting retention for COVID-19 for more than 6 hours, hospitalization, and/or suspected complications due to clinical progression of COVID-19 within 28 days…
Is treat-to-target LDL-C strategy noninferior to high-intensity statin therapy for long-term clinical outcomes in patients with coronary artery disease? Study design: Randomized, multicenter, noninferiority trial Population Interventions Primary outcome: 3-year composite of death, myocardial infarction, stroke, or coronary revascularization Secondary outcomes Safety outcomes or Adverse Events Safety Outcomes Treat-to-Target Group (%) High-Intensity Statin Group (%)…
How does the diagnostic accuracy of chest ultrasonography (CUS) compare to chest X-ray (CXR) for detecting pneumothorax in trauma patients in the emergency department (ED)? Study design: Systematic review and meta-analysis of 13 prospective, paired comparative accuracy studies Population Interventions Primary outcome: Sensitivity and specificity of CUS and CXR for pneumothorax detection Conclusion The diagnostic…
Does torsemide reduce all-cause mortality compared with furosemide in patients with heart failure following hospitalization? Study design: Open-label, pragmatic randomized trial Population Interventions Primary outcome: All-cause mortality in a time-to-event analysis Conclusion Among patients discharged after hospitalization for heart failure, torsemide compared with furosemide did not result in a significant difference in all-cause mortality over…
